CRISPR Gene-Editing Technology Moves Closer to Clinical Reality
CRISPR's precision genome and epigenome editing capabilities are advancing faster than expected, with multiple therapies now in clinical trials. This matters because the technology could transform how companies develop treatments for previously untreatable genetic diseases and reshape precision medicine markets within the next decade.
Originaltitel: Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine
<p>CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated proteins) has undergone marked advancements since its discovery as an adaptive immune system in bacteria and archaea, emerged as a potent gene-editing tool after the successful engineering of its synthetic guide RNA (sgRNA) toward the targeting of specific DNA sequences with high accuracy. Besides its DNA editing ability, further-developed Cas variants can also edit the epigenome, rendering the CRISPR-Cas system a versatile tool for genome and epigenome manipulation and a pioneering force in precision medicine. This review explores the latest advancements in CRISPR-Cas technology and its therapeutic and biomedical applications, highlighting its transformative impact on precision medicine. Moreover, the current status of CRISPR therapeutics in clinical trials is discussed. Finally, we address the persisting challenges and prospects of CRISPR-Cas technology.</p>